DC4U Technologies is a life science company that specializes in developing innovative technologies to steer the human immune response. Our flagship product, GlycoDC TM, is a cutting-edge dendritic cell targeting technology that enables the potentiation or suppression of the immune system through specific glycan modified antigen conjugates. With GlycoDC TM, we can significantly enhance anti-tumor immunity, restore tolerance in allergic patients, and even enhance traditional prophylactic vaccines to be more effective.

Our technology has a wide range of applications, including therapeutic cancer vaccines, allergy therapeutics, food allergy treatments, prophylactic vaccines, autoimmune therapeutics, and inflammation therapeutics. By utilizing the power of GlycoDC TM, we can achieve targeted immune responses to combat various diseases and conditions. Stay updated with our latest news and breakthroughs in the field of immune response modulation.

We are excited to have received a €1. 7 million Eurostars grant to jointly develop an innovative treatment for Type I diabetes in collaboration with LUMC consortium. We are also proud to announce advancements in the development of next-generation grass pollen vaccine and therapeutic vaccine for multiple sclerosis.

Join us in unlocking the full potential of the human immune system. Contact us today to learn more about our groundbreaking technology and the business opportunities we offer